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Respirovirus C protein blocks the type I interferon-stimulated activation of the 20 
JAK-STAT pathway. It has been reported that C protein inhibits interferon-α-stimulated 21 
tyrosine phosphorylation of STATs, but the underlying mechanism is poorly understood. 22 
Here we show that C protein of Sendai virus, a member of the Respirovirus genus, binds 23 
to the IFN-α/β receptor subunit (IFNAR2) and inhibits interferon-α-stimulated tyrosine 24 
phosphorylation of the upstream receptor-associated kinases, JAK1 and TYK2. Analysis 25 
of various Sendai virus C mutant (Cm) proteins demonstrates the importance of the 26 
inhibitory effect on receptor-associated kinase phosphorylation for blockade of 27 
JAK-STAT signaling. Furthermore, this inhibitory effect and the IFNAR2 binding 28 
capacity were observed for all the respirovirus C proteins examined. Our results suggest 29 
that respirovirus C protein inhibits activation of the receptor-associated kinases JAK1 and 30 
TYK2 possibly through interaction with IFNAR2. 31 
 32 
 33 






The Respirovirus genus in the family Paramyxoviridae includes human parainfluenza 38 
virus type 1 (HPIV1) and human parainfluenza virus type 3 (HPIV3), which are 39 
important in the field of pediatrics medicine [1]. HPIV1 is known as an infectious agent 40 
causing viral croup syndrome. HPIV3 can cause severe lower respiratory tract infection 41 
like human respiratory syncytial virus, particularly in infants with congenital heart 42 
diseases and low-birth-weight babies. Pathogenesis of these respiroviruses involves 43 
complicated processes affected by multiple factors. Of such factors, viral evasion 44 
strategies against the host interferon (IFN) system have been recently paid a lot attention.  45 
 Type I IFNs, IFN-α and IFN-β, are produced and secreted by virus infected cells 46 
and induce an anti-viral state in nearby cells via activation of the JAK-STAT signaling 47 
pathway by binding to the IFN receptor consisting of two subunits, IFN-α/β receptor 48 
subunit (IFNAR) 1 and IFNAR2 [2-4]. The binding brings the receptor-associated 49 
kinases, JAK1 and TYK2, into close proximity, resulting in cross-phosphorylation of 50 
JAK1 and TYK2. These activated kinases phosphorylate specific tyrosine residues of 51 
STAT2 and STAT1. Phosphorylated STAT2 and STAT1 leave the receptor as heterodimer, 52 
which associates with IRF9 to form interferon-stimulated gene factor 3 (ISGF3). ISGF3 53 
is translocated into the nucleus and binds to the promoter containing IFN-stimulated 54 
response element (ISRE) to activate IFN-stimulated genes such as the anti-viral PKR 55 
gene. 56 
 Sendai virus (SeV), a murine respirovirus, was the first case in which 57 
respirovirus accessory protein C was found to block the type I IFN JAK-STAT signaling 58 
pathway [5,6]. Subsequent studies have demonstrated that this anti-IFN activity is a 59 
characteristic common to all the members of the Respirovirus genus including HPIV1 and 60 
 
 4 
HPIV3 [7-10], suggesting its important role in survival of members of the Respirovirus 61 
genus through evolution. Silencing the C gene or eliminating its anti-IFN activity by the 62 
reverse-genetic technology resulted in attenuation of the virus virulence, demonstrating 63 
that the anti-IFN activity is deeply involved in viral pathogenesis [9,11-13]. 64 
Understanding of viral immune evasion mechanism thus will contribute to not only 65 
elucidation of viral pathogenesis but also development of effective vaccines and antiviral 66 
agents. 67 
Twenty years have passed since the anti-IFN activity of SeV was discovered. 68 
Nevertheless, full understanding of its molecular mechanism has not yet been reached. 69 
Garcin et al. reported the significance of STAT1 degradation induced by expression of 70 
the SeV C protein in some cell types [14,15]. However STAT1 degradation has not been 71 
observed in a variety of cell types such as HeLa and HEK293T cells, and also in any 72 
type of the cells expressing the C protein of HPIV1 and HPIV3 [7,8,10,16]. Therefore, 73 
it is clear that there is a mechanism by which the C protein blocks the JAK-STAT 74 
signaling pathway without leading to STAT1 degradation. Previous studies performed in 75 
our lab have demonstrated that the SeV C protein binds to STAT1 and inhibits 76 
IFN-α-stimulated tyrosine-phosphorylation of STAT2 and STAT1 [15,17-19]. Analysis of 77 
the C mutant proteins has demonstrated the significance of the inhibition of 78 
tyrosine-phosphorylation of STAT2, and has raised the possibility that STAT1 is a target 79 
of the SeV C protein [19]. Afterwards target molecule of the SeV C protein has become 80 
uncertain because it was found that several C mutant proteins, which exhibited the 81 
decreased STAT1-binding capacity, retained the ability to block the type I IFN 82 
JAK-STAT signaling pathway [20]. It also remains unclear what is the real target of the 83 
HPIV1 and HPIV3 C proteins and how the HPIV1 and HPIV3 C proteins inhibit type I 84 
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IFN-stimulated JAK-STAT pathway, although it has been reported that the HPIV1 C 85 
protein binds to STAT1 and inhibits phosphorylation of STAT1 and STAT2 [21], and 86 
that the HPIV3 C protein inhibits phosphorylation of STAT1 [7]. 87 
Under these circumstances, we attempted to find out target molecules of the 88 
respirovirus C proteins for the inhibition of the JAK-STAT signaling to elucidate the 89 
underlying molecular mechanism. It was found that the SeV C protein interacted with 90 
IFNAR2 and JAK1 as well as STAT1, and inhibited IFN-α-stimulated phosphorylation 91 
of the upstream receptor-associated kinases, JAK1 and TYK2. Analysis of various SeV 92 
C mutant proteins and other respirovirus C proteins has ruled out the possibility of 93 
STAT1 and JAK1 as a major target, and have demonstrated the importance of the 94 
inhibition of tyrosine-phosphorylation of the receptor-associated kinases JAK1 and 95 
TYK2.  96 
 97 
Materials and Methods 98 
Cells and a virus 99 
HEK293T and U3A (STAT1-null 2fTGH) cells were maintained in Dulbecco’s modified 100 
Eagle’s medium supplemented with 2 mM L-glutamine, penicillin (100 IU/ml), 101 
streptomycin (100 μg/ml), and 10% fetal bovine serum [22]. Vesicular stomatitis virus 102 
(VSV) was propagated in Vero cells [23]. 103 
Plasmids 104 
In order to express viral or cellular protein with or without FLAG, V5 or 105 
Glutathione-S-transferase (GST) tag, mammalian expression plasmids were created by 106 
insertion of a DNA fragment carrying the respective gene into the multicloning site 107 
downstream of the cytomegalovirus enhancer chicken β-actin hybrid promoter of pCA7. 108 
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The DNA fragment encoding viral protein or one of the human signaling components 109 
constituting the JAK-STAT pathway was created by polymerase chain reaction (PCR) or 110 
reverse transcription (RT)-PCR. SeV and HPIV1 express multiple species of the C 111 
protein, because their C open reading frames contain four translational start sites to 112 
produce a nested set of four carboxy-coterminal four proteins, C’, C, Y1, and Y2 [24]. C 113 
is the most abundant protein of four proteins expressed in infected cells. Therefore 114 
C-expression plasmids for SeV and HPIV1 were created by insertion of DNA fragments 115 
encoding C but not C’ with or without FLAG or V5 tag into pCA7. Mutations were 116 
introduced by PCR-based overlap mutagenesis in the same way as before [25]. Sequence 117 
fidelity of all the plasmids was confirmed by sequence analysis. pIRESpuro3 plasmid 118 
carrying the puromycin-resistant gene was purchased from Clontech Laboratories, 119 
Mountain View, CA. 120 
Luciferase reporter gene assay 121 
ISRE promoter-driven firefly luciferase (Fluc) reporter plasmid (pISRE-TA-Luc) 122 
(Clontech Laboratories, Mountain View, CA) (80 ng/well) and pRL-TK (Promega 123 
Corporation, Madison, WI) (10 ng/well) were transfected into HEK293T cells (~1.0 x 124 
105) cultured in a 24-well plate in triplicate together with a plasmid expressing wild type 125 
or mutant C protein (50 ng/well) by using polyethyleneimine (Polysciences, Warrington, 126 
PA) [25,26]. The total mass of transfected DNA was held constant in all experiments by 127 
adding an appropriate amount of pCA7 empty plasmid. At 24 h post-transfection, 128 
transfected cells were treated with recombinant human IFN-α2b (1,000 U/ml; 129 
Schering-Plough, Kenilworth, NJ) for 6 h, and then lysed. Luciferase activities of the cell 130 
lysates were measured by the dual-luciferase reporter assay system (Promega 131 
Corporation, Madison, WI) according to the manufacturer’s protocol. Relative luciferase 132 
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activity was determined as the ratio of Fluc activity to Renilla luciferase (Rluc) activity. 133 
Immunoprecipitation and GST pull-down assay 134 
HEK293T or U3A cells (~5.0 x 105/well) in a 6-well plate were transfected with various 135 
combinations of plasmids (500 ng/well each), using polyethyleneimine. At 24 h 136 
post-transfection, cells were lysed in 400 μl of a lysis buffer (50 mM Tris-HCl pH 7.4, 137 
150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail). For 138 
immunoprecipitation, the cell lysates were incubated with anti-V5 mouse monoclonal 139 
antibody (mAb) (SV5-Pk1: Invitrogen, Carlsbad, CA), anti-FLAG mouse mAb (1E6: 140 
Wako Pure Chemical Industries, Osaka, Japan), or anti-myc mouse mAb (2276: Cell 141 
signaling Technology, Danvers, MA) together with SureBeads Protein G (Bio-Rad, 142 
Hercules, CA) at 4˚C for 2 hr. In some experiments, protein products synthesized in 143 
vitro by the TNT SP6 high-yield wheat germ protein expression system (Promega 144 
Corporation, Madison, WI) were used in place of cell lysates [27]. For GST pull-down 145 
assay, the cell lysates were incubated with Glutathione Sepharose beads (GE Healthcare 146 
Life Sciences, Buckinghamshire, England) at 4˚C for 2 hr. After washing the beads five 147 
times with the lysis buffer, proteins were eluted from the beads by boiling with Laemmli 148 
sample buffer [50 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate (SDS), 0.1% 149 
bromophenol blue, 10% glycerol and 5% 2-mercaptoethanol], and then subjected to 150 
immunoblot analysis.  151 
Immunoblot analysis 152 
Samples were resolved by SDS-(10-15%)-polyacrylamide gel electrophoresis, and then 153 
electroblotted onto a membrane filter (Immobilon-P: Millipore, Burlington, MA). The 154 
membrane was blocked in PVDF Blocking Reagent (Toyobo, Osaka, Japan) before 155 
incubation at 4˚C overnight with anti-VSV mouse serum, anti-C rabbit serum, 156 
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anti-FLAG mouse mAb (1E6), anti-V5 mouse mAb (SV5-Pk1), anti-GST mouse mAb 157 
(5A7; Wako Pure Chemical Industries, Osaka Japan), anti-STAT1 rabbit polyclonal Ab 158 
(sc-346; SantaCruz Biotechnology, Dallas, TX), anti-STAT2 rabbit polyclonal Ab 159 
(4594; Cell signaling Technology, Danvers, MA), anti-phospho-STAT2 (Tyr690) rabbit 160 
polyclonal Ab (07-224; Millipore, Burlington, MA), or anti-phospho-STAT1 (Tyr701) 161 
rabbit mAb (7649; Cell signaling Technology, Danvers, MA), anti-JAK1 rabbit mAb 162 
(3344; Cell signaling Technology, Danvers, MA), anti-TYK2 rabbit mAb (14193; Cell 163 
signaling Technology, Danvers, MA), anti-phospho-JAK1 goat polyclonal Ab 164 
(sc-16773; SantaCruz Biotechnology, Dallas, TX), anti-phospho-TYK2 rabbit mAb 165 
(68790; Cell signaling Technology, Danvers, MA), or anti-GAPDH rabbit mAb (5147: 166 
Cell signaling Technology, Danvers, MA). The membrane was then incubated at room 167 
temperature for 2 h with horseradish peroxidase-conjugated anti-mouse IgG Ab, 168 
anti-rabbit IgG Ab (GE Healthcare Life Sciences, Buckinghamshire, England), or 169 
anti-goat IgG Ab (Jackson ImmunoResearch, West Grove, PA). Immunoreactive bands 170 
were visualized by using the ECL select substrate (GE Healthcare Life Sciences, 171 
Buckinghamshire, England). 172 
 173 
Results 174 
STAT1 is not a major target of the SeV C protein  175 
The SeV C protein binds to STAT1 and inhibits IFN-α-stimulated 176 
tyrosine-phosphorylation of STAT1 and STAT2 [15,17,18,28]. These findings suggest 177 
that STAT1 is one of the target molecules of the C protein. However, subsequent study 178 
revealed that several SeV C mutant proteins retained the ability to block the type I IFN 179 
JAK-STAT pathway, although exhibited the decreased STAT1-binding capacity [20]. To 180 
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confirm whether this result is correct, we have constructed a variety of plasmids 181 
expressing the C mutant protein (Fig.1 A). A series of Cm proteins has point mutations, 182 
which result in replacement of two or three charged amino acids with alanine [20]. CF170S 183 
has a single point mutation, which causes amino acid substitution of serine for 184 
phenylalanine at the position 170. This mutation is derived from an avirulent mutant SeV 185 
generated through successive passages of a highly virulent field strain, Ohita-M1 [29]. 186 
Initially, we examined effect of these C mutant proteins on IFN-α-stimulated activation of 187 
the promoter containing ISRE. pISRE-TA-Luc and internal control pRL-TK were 188 
transfected into HEK293T cells along with one of the C mutant proteins. Transfected 189 
cells were treated with IFN-α for 6 h, and then subjected to luciferase reporter assay. As 190 
shown in Fig.1 B, Cm3, Cm4, Cm6, Cm7, and Cm9 retained the inhibitory effect on 191 
IFN-α-stimulated activation of the Fluc gene, comparable to that of wild type C. In 192 
contrast, inhibitory effect was not observed for Cm5, Cm8, and CF170S, indicating that 193 
Cm5, Cm8, and CF170S has lost the ability to block the type I IFN JAK-STAT pathway. 194 
This finding was also confirmed by examining effect on establishment of the 195 
IFN-α-induced antiviral state in cells (Fig.1 C). HEK293T cells were transfected with one 196 
of the C mutant proteins, and subsequently treated with IFN-α. After IFN-α treatment for 197 
24 h, the cells were infected with VSV, one of the IFN-sensitive viruses. At 6 h 198 
post-infection, the level of VSV proteins was estimated by immunoblot analysis. As 199 
expected, the level of viral protein synthesis was comparable between Cm3, Cm4, Cm6, 200 
Cm7, Cm9, and wild type C, whereas it was significantly suppressed in Cm5, Cm8, and 201 
CF170S. 202 
We also tested the ability of the C mutant proteins to bind to STAT1 (Fig.1 D). 203 
HEK293T cells were transfected with one of the FLAG-tagged C mutants, and then 204 
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subjected to immunoprecipitation with anti-FLAG antibody. As shown in Fig.1 D, STAT1 205 
was co-precipitated in cells transfected with Cm3 and Cm4 as efficiently as in cells 206 
transfected with wild type C, whereas only a negligible amount of STAT1 was 207 
co-precipitated in Cm5, Cm6, Cm7, and Cm8. It should be noted that Cm6 and Cm7, 208 
which retained the inhibitory effect on JAK-STAT signaling (Fig.1 B), exhibited the 209 
decreased STAT1 binding capacity. Furthermore, intermediate levels of STAT1 were 210 
co-precipitated in Cm9 and CF170S, although there was a marked contrast between them in 211 
the ability to block JAK-STAT signaling (Fig.1 BC). From these results, we have 212 
concluded that STAT1 is not a major target of the SeV C protein.  213 
 214 
IFNAR2 and JAK1 are potential targets of the SeV C protein 215 
To find a molecular target of the SeV C protein, we investigated the interaction between 216 
the C protein and components of the type I IFN JAK-STAT signaling pathway. SeV C was 217 
transfected into HEK293T cells along with one of the FLAG-tagged signaling 218 
components, and then transfected cells were subjected to immunoprecipitation. As shown 219 
in Fig.2 A, the C protein was co-precipitated with anti-FLAG antibody in cells transfected 220 
with FLAG-tagged IFNAR2, JAK1, and STAT1. Conversely, V5-tagged IFNAR2, JAK1, 221 
and STAT1 were co-precipitated with anti-FLAG antibody when FLAG-tagged C was 222 
transfected into HEK293T cells along with one of the V5-tagged signaling components 223 
(Fig.2 B). To rule out the possibility that the C-IFNAR2 and C-JAK1 interactions were 224 
mediated by endogenous STAT1, immunoprecipitation experiments were carried out for 225 
U3A (STAT1-null 2fTGH) cells transfected with FLAG-C and one of the V5-tagged 226 
signaling components (Fig.2 CD). FLAG-C was co-precipitated with anti-V5 antibody 227 
even in STAT1-null cells transfected with IFNAR2-V5 and FLAG-C or with JAK1-V5 228 
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and FLAG-C. Co-transfection of exogenous STAT1 into U3A cells did not affect the 229 
amount of co-precipitated FLAG-C in cells transfected with IFNAR2-V5 and FLAG-C 230 
(Fig.2 C). In contrast, the amount of co-precipitated FLAG-C was decreased by 231 
co-transfection of STAT1 in cells transfected with JAK1-V5 and FLAG-C (Fig.2 D), 232 
suggesting that JAK1 and STAT1 may compete with each other for binding to the C 233 
protein. Taken together, these results suggest that the C-IFNAR2 and C-JAK1 234 
interactions are not mediated by STAT1. Thus IFNAR2 and JAK1 were found to be 235 
potential targets of the C protein. 236 
 237 
The SeV C protein interacts with cytoplasmic domain of IFNAR2 and with kinase 238 
domain of JAK1239 
We next attempted to identify domains of IFNAR2 and JAK1 responsible for interaction 240 
with the SeV C protein. HEK293T cells were transfected with SeV C and one of 241 
FLAG-tagged IFNAR2 deletion mutants (Fig.3 A), and then subjected to 242 
immunoprecipitation. As shown in Fig.3 B, the C protein was co-precipitated with 243 
anti-FLAG antibody in cells transfected with FLAG-tagged IFNAR21-346, and 244 
IFNAR21-462, and not IFNAR21-265, suggesting that the C protein interacts with aa 245 
265-346 region of the IFNAR2 cytoplasmic tail. Multiple bands were observed for 246 
FLAG-tagged IFNAR2 deletion mutants. This is probably due to protein modifications 247 
such as glycosylation, precise nature of which was not determined. Importance of the aa 248 
265-346 region was also supported by GST pull-down assay using extracts from cells 249 
transfected with FLAG-C and one of the GST-tagged IFNAR2 deletion mutants (Fig.3 C). 250 
As shown in Fig.3 D, FLAG-C was co-purified with GST-IFNAR2266-515 but neither with 251 
GST-IFNAR2347-515 nor with GST-IFNAR2463-515. Immunoprecipitation experiments 252 
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were further performed for HEK293T cells transfected with SeV C and one of V5-tagged 253 
JAK1 deletion mutants (Fig.4 A). As shown in Fig.4 B, FLAG-C was co-precipitated 254 
with anti-V5 antibody in cells transfected with V5-tagged JAK1427-1154, JAK1556-1154, or 255 
JAK1859-1154, indicating that the C protein interacts with the kinase domain (aa 859-1154) 256 
of JAK1.  257 
 258 
Molecular target of the SeV C protein  259 
The C-JAK1 and C-IFNAR2 interactions are not mediated by STAT1 as described above 260 
(Fig.2 C), but the possibility remains that they are mediated by unknown intracellular 261 
molecules other than STAT1. To determine whether their interactions were direct, 262 
immunoprecipitation experiments were carried out for products synthesized in vitro by 263 
the wheat germ cell-free expression system. IFNAR2266-515-FLAG, JAK1859-1154-FLAG, 264 
and V5-C were synthesized by the wheat germ transcription/translation system (Input in 265 
Fig.5). They were mixed in various combinations, and subjected to immunoprecipitation 266 
(Fig.5). V5-C was co-precipitated with anti-FLAG antibody in mixtures of V5-C and 267 
IFNAR2266-515-FLAG. Conversely IFNAR2266-515-FLAG was co-precipitated with 268 
anti-V5 antibody. These results suggest that the C-IFNAR2 interaction is direct. In 269 
contrast, co-precipitation of V5-C and JAK1859-1154-FLAG was not observed for mixtures 270 
of V5-C and JAK1859-1154-FLAG, raising the possibility that the C-JAK1 interaction is 271 
mediated by unknown cellular molecules. 272 
To determine whether the C-JAK1 and C-IFNAR2 interactions are essential for 273 
the blockade of type I IFN JAK-STAT signaling, the ability of the C mutant proteins to 274 
bind to JAK1 or IFNAR2 was tested by immunoprecipitation experiments. As shown in 275 
Fig.6 A, JAK1-V5 was co-precipitated with anti-FLAG antibody in cells co-transfected 276 
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with FLAG-tagged Cm3, Cm4, Cm6, or Cm9, whereas only a negligible amount of 277 
JAK1-V5 was co-precipitated in Cm5, Cm7, Cm8, or CF170S. It should be noted that Cm7, 278 
which retained full inhibitory effect on JAK-STAT signaling as described above (Fig.1 279 
BC), exhibited the decreased JAK1 binding capacity, demonstrating that JAK1 is not a 280 
major target of the SeV C protein. On the other hand, IFNAR2-V5 was co-precipitated 281 
with anti-FLAG antibody in cells transfected with any of the FLAG-tagged C mutant 282 
proteins (Fig.6 B). To check whether binding of SeV C and C mutant proteins to IFNAR2 283 
is specific, we determined whether SeV P protein binds to IFNAR2 as a control. As 284 
shown in Fig.6 C, IFNAR2-V5 was not co-precipitated in cells co-transfected with 285 
FLAG-tagged SeV P protein. These results neither have supported nor have ruled out the 286 
hypothesis that IFNAR2 is a major target of the C protein.  287 
 288 
The SeV C protein prevents neither STAT2 nor JAK1 from interacting with 289 
IFNAR2 290 
Cytoplasmic tail of IFNAR2 is the region with which JAK1 and STAT2 interact [30-32], 291 
It raised the possibility that the C protein might prevent JAK1 or STAT2 from interacting 292 
with IFNAR2. Immunoprecipitation experiments were performed using extracts from 293 
cells transfected with STAT2-V5 and IFNAR2-FLAG or with JAK1-V5 and 294 
IFNAR2-FLAG to monitor STAT2-IFNAR2 and JAK1-IFNAR2 interactions (Fig.7). 295 
IFNAR2-FLAG were co-precipitated with anti-V5 antibody in either case (the second 296 
lanes, Fig.7 AB), indicating that both STAT2 and JAK1 interact with IFNAR2. However, 297 
co-transfection with C or one of the C mutant proteins did not affect the amount of 298 
IFNAR2-FLAG co-precipitated (Fig.7 AB). These results suggest that the C protein 299 




The SeV C protein inhibits type I IFN-stimulated tyrosine-phosphorylation of the 302 
receptor-associated kinases  303 
Formation of the ISGF3 complex requires phosphorylation of tyrosine residues in the 304 
C-terminal regulatory domain of STAT1 and STAT2. This phosphorylation is inhibited in 305 
cells expressing the C protein [18,19]. We thus checked phosphorylation status of both 306 
STATs in cells transfected with one of the C mutant proteins at 15 min after IFN-α 307 
stimulation (Fig.8). Cm3, Cm4, Cm6, Cm7, and Cm9 retained inhibitory effect on 308 
IFN-α-stimulated tyrosine-phosphorylation of STAT1 and STAT2, comparable to that of 309 
wild type C, whereas Cm5, Cm8, and CF170S exhibited the decreased inhibitory effect. 310 
This is in good agreement with the result of Fig.1 BC. STAT1 and STAT2 are 311 
phosphorylated by the receptor-associated kinases, JAK1 and TYK2. Since these kinases 312 
are activated by cross-phosphorylation through IFN-α-mediated association of IFNAR1 313 
and IFNAR2, we tested effect of the C mutant proteins on IFN-α-stimulated 314 
tyrosine-phosphorylation of JAK1 and TYK2. As shown in Fig.8, 315 
tyrosine-phosphorylation of both JAK1 and TYK2 was inhibited in cells transfected with 316 
C, Cm3, Cm4, Cm6, Cm7, and Cm9. This result is also in good agreement with the result 317 
of Fig.1 BC. Taken together, these findings have demonstrated the importance of the 318 
inhibitory effect on tyrosine-phosphorylation of the receptor-associated kinases for the 319 
blockade of JAK-STAT signaling.  320 
 321 
Common characteristics of respirovirus C proteins 322 
The C protein of HPIV1 and HPIV3 belonging to the same Respirovirus genus blocks 323 
the type I IFN JAK-STAT pathway [7,21]. These findings were confirmed by the 324 
 
 15 
reporter assay as shown in Fig.9 A. To determine whether the underlying molecular 325 
mechanism is common to members of the Respirovirus genus, we examined interaction 326 
of the HPIV1, HPIV3, and BPIV3 C proteins with components of the JAK-STAT 327 
pathway. Immunoprecipitation experiments showed that HPIV1, HPIV3, and BPIV3 C 328 
proteins were capable of binding to IFNAR2 (Fig.9 B). In contrast, the HPIV1, HPIV3, 329 
and BPIV3 C proteins exhibited only a little or negligible binding capacity for STAT1 330 
and JAK1 (Fig.9 CD). We also examined effect of the HPIV1, HPIV3, and BPIV3 C 331 
proteins on IFN-α-stimulated tyrosine-phosphorylation of the signaling components. 332 
Inhibition of tyrosine-phosphorylation of STAT1, STAT2, and the receptor-associated 333 
kinases, JAK1 and TYK2, was observed for the HPIV1, HPIV3, and BPIV3 C proteins 334 
as well (Fig.9 E). These results suggest that the abilities of the C protein to bind to 335 
IFNAR2 and to inhibit the receptor-associated kinase activation are common 336 
characteristics of members of the Respirovirus genus. 337 
 338 
Discussion 339 
The present study has demonstrated that the respirovirus C protein inhibits activation 340 
process of the receptor-associated kinases, JAK1 and TYK2. This finding is consistent 341 
with our previous observation that IFN-α-stimulated tyrosine-phosphorylation of TYK2 342 
is partly suppressed in SeV-infected cells [33], and explains how the C protein inhibits 343 
IFN-α-stimulated tyrosine-phosphorylation of STAT1 and STAT2. There is no difference 344 
between the SeV, HPIV1, HPIV3, and BPIV3 C proteins in their abilities to inhibit type 345 
I IFN-stimulated tyrosine-phosphorylation of JAK1 and TYK2. This suggests that the 346 
underlying mechanism has been conserved between respiroviruses and has played a 347 
critical role in virus survival through evolution, although amino acid sequence identity 348 
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between SeV C and HPIV3 C or between SeV C and BPIV3 C is low at present (38.4% 349 
or 35.3%, respectively) [24].  350 
IFNAR2 is the only signaling component, to which all the respirovirus C 351 
proteins examined can bind (Fig.9 BCD), suggesting that target molecule is IFNAR2. 352 
However, convincing evidence could not be obtained, because all the SeV C mutant 353 
proteins created here have retained the IFNAR2 binding capacity. The possibility 354 
remains that unknown molecules functioning near the receptor or receptor-associated 355 
kinases is a target of the C protein. It is also unclear how the C protein inhibits 356 
cross-activation of JAK1 and TYK2. Since the SeV C protein binds to the cytoplasmic 357 
tail of IFNAR2 nearby cell membrane (Fig.3), we hypothesized that the C protein could 358 
prevent JAK1 or STAT2 from interacting with IFNAR2. However, immunoprecipitation 359 
experiments showed that neither IFNAR2-STAT2 interaction nor IFNAR2-JAK1 360 
interaction was affected by expression of the C protein (Fig.7 AB). It is possible that the 361 
C protein might hinder type I IFN-mediated association between IFNAR1 and IFNAR2, 362 
which is required for cross-activation of the receptor-associated kinases, or might affect 363 
distribution of IFNAR2 by inhibiting transport of IFNAR2 from rough endoplasmic 364 
reticulum to the cell surface. These possibilities should be taken into consideration in 365 
the future study. 366 
Immunoprecipitation experiments did not detect interaction of the HPIV1 C 367 
protein with STAT1 (Fig.9 C). This result, although seemingly conflicts with the 368 
previous finding by Schomacker et al. [21], is reconcilable with it. The C open reading 369 
frame of HPIV1 and SeV unlike HPIV3 and BPIV3 contains four translational start sites 370 
to produce a nested set of carboxy-coterminal four proteins termed C’, C, Y1, and Y2, 371 
which are listed in descending order in size. Schomacker et al. reported that they tried to 372 
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identify C binding partners by several methods including yeast-two-hybrid assays and 373 
immunoprecipitation, but failed at first [21]. They could succeed in 374 
co-immunoprecipitate STAT1 with C’ (largest form of the C protein) but not C only 375 
when C’ was over-expressed in 293T cells and washing conditions for the 376 
immunoprecipitation were adjusted. These results may suggest the possibility that the 377 
N-terminal region (aa 1-15) of C’(aa 1-219), which C (aa 16-219) does not have, is 378 
responsible for the C’-STAT1 interaction. Thus their findings do not necessarily conflict 379 
with our results obtained using plasmids expressing C but not C’.  380 
Analysis of the SeV C mutant proteins has demonstrated that the C-STAT1 and 381 
C-JAK1 interactions are not required for the blockade of the JAK-STAT pathway (Fig.1 382 
and Fig.6). Do the C-STAT1 and C-JAK1interactions make no contribution to the 383 
blockade of the type I IFN JAK-STAT signaling pathway? Oda et al. have determined 384 
the crystal structure of the N-terminal domain of STAT1 associated with the C-terminal 385 
half of the C protein [34], and have proposed the hypothesis that one molecule of the C 386 
protein might associate with the dimeric structure formed between the N-terminal 387 
domains of STAT1 and STAT2, thereby leading the STAT1-STAT2 heterodimer into an 388 
anti-parallel form, which is easily dephosphorylated [35]. It is also possible that the C 389 
protein might inhibit kinase activity through interaction with the kinase domain of 390 
JAK1. However, it would be necessary to isolate C mutant proteins that retain the 391 
binding capacity for only one of three binding proteins (IFNAR2, JAK1, and STAT1) to 392 
assess contribution of the C-JAK1 and C-STAT1 interactions to the signaling inhibition. 393 
The Paramyxoviridae family includes the Respirovirus, Morbillivirus, 394 
Henipavirus, Rubulavirus, and Avulavirus genera. Members of the Respirovirus genus 395 
uses the C protein and not the V protein as an IFN antagonist that blocks the type I IFN 396 
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JAK-STAT pathway, whereas members of the other genera use the V protein instead of 397 
the C protein. The present study has demonstrated that inhibition of activation of the 398 
receptor-associated kinases is a common characteristic of the respirovirus C proteins. 399 
The V protein of PIV5, mumps virus and HPIV2 in the Rubulavirus genus and 400 
Newcastle disease virus in the Avulavirus genus promotes degradation of either STAT1 401 
or STAT2 [36-39], whereas the V protein of measles virus in the Morbillivirus genus 402 
inhibits STAT1 and STAT2 phosphorylation without STAT degradation [40,41]. The V 403 
protein of Hendra and Nipah viruses in the Henipavirus genus binds to both STAT1 and 404 
STAT2, inhibits their phosphorylation, and induces their cytoplasmic aggregates [42,43]. 405 
Thus, there may be common specific mechanism at least within the same genus. 406 
Knockout of the C gene results in attenuation of virus pathogenicity. Therefore, 407 
the recombinant virus, whose C gene is silenced, is a candidate for attenuated virus 408 
vaccine. However, the C-knockout recombinant SeV and HPIV1 show too poor growth 409 
in cell culture and hence cannot be prepared as vaccines [13,44]. The C protein is a 410 
multi-functional protein that exerts anti-IFN effect [5,6,45-47], regulates viral RNA 411 
synthesis [48,49], facilitates virus budding [44,50-53], and inhibits virus-induced 412 
apoptosis [54]. Such various functions collectively contribute to virus pathogenicity, 413 
resulting in over-attenuation of the recombinant viruses. Thus, moderately attenuated 414 
recombinant viruses, which could be created by silencing only a single function with the 415 
other functions remained, might be suitable for vaccine. For this purpose, it would be 416 
necessary to determine domains or amino acid residues important for maintaining each 417 
function of the C protein. 418 
In conclusion, the present study has uncovered that members of the Respirovirus 419 
genus have evolved the C proteins as an IFN antagonist, which inhibits IFN-α-stimulated 420 
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tyrosine-phosphorylation of the upstream receptor-associated kinases possibly through 421 
interaction with IFNAR2 to block the type I IFN JAK-STAT signaling pathway. 422 
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Figure legends 612 
Fig.1 613 
Effect of the SeV C mutant proteins on type I IFN JAK-STAT signaling, and their 614 
STAT1-binding capacity. (A) Amino acid sequence of SeV CF170S and C mutant (Cm) 615 
proteins. Charged amino acids shown in bold letters have been replaced by A in a series of 616 
the Cm proteins. F at the position 170 has been replaced by S in the CF170S protein. (B) C 617 
or one of the C mutants was transfected into HEK293T cells along with pISRE-TA-Luc 618 
and pRL-TK. At 24 h post-transfection, cells were treated with IFN-α2b (1,000 U/ml) for 619 
6 h, and then subjected to luciferase reporter assay. Mean values from three independent 620 
experiments are shown with standard deviations as error bars. (C) HEK293T cells were 621 
transfected with FLAG-tagged C or one of the C mutants. At 24 h post-transfection, cells 622 
were treated with IFN-α2b (1,000 U/ml) for 24 h, and then infected with VSV at a 623 
multiplicity of infection of 10. At 6 h post-infection, cells were lysed and subjected to 624 
immunoblot analysis (IB) with anti-VSV antibody. (D) HEK293T cells were transfected 625 
with FLAG-tagged C or one of the C mutants. At 24 h post-transfection, cells were lysed, 626 
and then subjected to immunoprecipitation (IP) with anti-FLAG antibody followed by IB 627 
with anti-FLAG or anti-STAT1 antibody. A portion of each whole cell lysate prepared for 628 
IP was also subjected to IB. 629 
Fig.2 630 
Interaction of the SeV C protein with components of the type I IFN JAK-STAT pathway. 631 
HEK293T (A, B) or U3A (C, D) cells were transfected with indicated plasmids. At 24 h 632 
post-transfection, cells were lysed, and then subjected to IP with anti-FLAG (A, B) or 633 
anti-V5 (C, D) antibody followed by IB with anti-FLAG, anti-C, anti-V5, or anti-STAT1 634 




Interaction of the SeV C protein with IFNAR2 deletion mutants. (A and C) Schematic 637 
diagram of FLAG-tagged or GST-tagged IFNAR2 deletion mutants. SP; signal peptide, 638 
ED; extracellular domain, TM; transmembrane domain, CT; cytoplasmic tail. (B and D) 639 
HEK293T cells were transfected with indicated plasmids. At 24 h post-transfection, cells 640 
were lysed, and then subjected to IP with anti-FLAG antibody or GST pull-down assay 641 
followed by IB with anti-C or anti-FLAG antibody. A portion of each whole cell lysate 642 
prepared for IP or GST pull-down assay was also subjected to IB.  643 
Fig.4 644 
Interaction of the SeV C protein with JAK1 deletion mutants. (A) Schematic diagram of 645 
V5-tagged JAK1 deletion mutants. FERM; 4.1 protein, ezrin, radixin, moesin domain, 646 
SH2; src homology 2 domain.(B) HEK293T cells were transfected with indicated 647 
plasmids. At 24 h post-transfection, cells were lysed, and then subjected to IP with 648 
anti-V5 antibody followed by IB with anti-V5 or anti-FLAG antibody. A portion of each 649 
whole cell lysate prepared for IP was also subjected to IB. 650 
Fig.5 651 
Interaction between SeV C and signaling components synthesized in vitro. 652 
JAK1859-1154-FLAG, IFNAR2266-515-FLAG, and V5-C were synthesized by the wheat 653 
germ cell-free expression system. The in vitro transcription/translation products were 654 
mixed in various combinations and then subjected to IP with anti-FLAG or anti-V5 655 
antibody followed by IB with anti-V5 or anti-FLAG antibody. A portion of in vitro 656 
transcription/translation products (shown as Input) was also subjected to IB. 657 
Fig.6 658 
Interaction of the SeV C mutant proteins with JAK1 or IFNAR2. JAK1-V5 (A) or 659 
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IFNAR2-V5 (B and C) was transfected into HEK293T cells along with FLAG-tagged P, 660 
FLAG-tagged C, or one of the FLAG-tagged C mutants. At 24 h post-transfection, cells 661 
were lysed and then subjected to IP with anti-FLAG antibody or anti-myc antibody 662 
followed by IB with anti-FLAG or anti-V5 antibody. A portion of each whole cell lysate 663 
prepared for IP was also subjected to IB. P; SeV phosphoprotein 664 
Fig.7 665 
Effect of the SeV C and C mutant proteins on STAT2-IFNAR2 or JAK1-IFNAR2 666 
interactions. STAT2-V5 and FLAG-IFNAR2 (A) or JAK1-V5 and FLAG-IFNAR2 (B) 667 
were transfected into HEK293T cells along with C or one of the C mutant proteins. At 24 668 
h post-transfection, cells were lysed, and then subjected to IP with anti-V5 antibody 669 
followed by IB with anti-FLAG or anti-V5 antibody. A portion of each whole cell lysate 670 
prepared for IP was also subjected to IB.  671 
Fig.8 672 
Effect of the SeV C mutant proteins on IFN-α-stimulated tyrosine-phosphorylation of 673 
STAT1, STAT2, JAK1, and TYK2. Indicated plasmids were transfected into HEK293T 674 
cells along with pIRESpuro3 carrying the puromycin-resistant gene. At 24 h 675 
post-transfection, cells were incubated in a medium containing puromycin (10 μg/ml) for 676 
24 h. After removal of puromycin, surviving cells were treated with IFN-α2b (1,000 677 
U/ml) for 15 min, and then subjected to IB with anti-phospho-JAK1, anti-JAK1, 678 
anti-phospho-TYK2, anti-TYK2, anti-phospho-STAT1, anti-STAT1, 679 
anti-phospho-STAT2, anti-STAT2, anti-FLAG, or anti-GAPDH antibody. 680 
Fig.9 681 
Effect of HPIV1-C, HPIV3-C, and BPIV3-C on type I IFN JAK-STAT signaling, and 682 
their interaction with signaling components. (A) Indicated plasmids were transfected into 683 
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HEK293T cells along with pISRE-TA-Luc and pRL-TK. At 24 h post-transfection, cells 684 
were treated with IFN-α2b (1,000 U/ml) for 6 h, and then subjected to luciferase reporter 685 
assay. Mean values from three independent experiments are shown with standard 686 
deviations as error bars. (B-D) HEK293T cells were transfected with indicated plasmids. 687 
At 24 h post-transfection, cells were subjected to IP with anti-FLAG antibody followed 688 
by IB with anti-STAT1, anti-FLAG, or anti-V5 antibody. A portion of each whole cell 689 
lysate prepared for IP was also subjected to IB. (E) Indicated plasmids were transfected 690 
into HEK293T cells along with pIRESpuro3. At 24 h post-transfection, cells were 691 
incubated in a medium containing puromycin (10 μg/ml) for 24 h. After removal of 692 
puromycin, surviving cells were treated with IFN-α2b (1,000 U/ml) for 15 min, and then 693 
subjected to IB with indicated antibodies. SeV-V; a translation product of the V mRNA, 694 
which is transcribed from the SeV P gene through a process known as RNA editing.  695 
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